Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Scientists in Oxford have developed a Multivalent Dengue Vaccine that can afford wide coverage against all dengue serotypes circulating worldwide.

Multivalent dengue vaccine article screenshotThis can provide the following advantages over other vaccine developments:

  • Affordability: a single component to protect against all dengue viruses, instead of a costly multi-valent vaccine.
  • Targeting the most conserved structures of the dengue virus.
  • No requirement for adjuvants, the platform has its own adjuvanticity.
  • A vaccine platform with proved safety in hundreds of volunteers in phase I and II clinical trials for other diseases.

For further information, please visit Isis Innovation Technologies for License.